Primary mediastinal B-cell lymphoma starts in ... lymphoma affects the brain and spinal cord. Diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) are a group of cancers that don ...

Most patients had subtypes of large B-cell lymphoma, including 8 with diffuse large B-cell lymphoma, 2 with transformed follicular lymphoma, 1 with high-grade B-cell lymphoma, and 1 with T-cell ...

In this Q&A, Carly Stafford Dixon discusses her lymphoma journey, recovery with CAR T therapy, and mission to raise support ...

Patients with primary cutaneous B-cell lymphoma showed a higher risk of developing prostate and hematologic cancers in a ...

Sarcopenia, a hallmark of cancer cachexia, is associated with poor outcomes in chimeric antigen receptor (CAR) T-cell therapy ...

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant (ASCT). With this approval, this Columvi combination is the first bispecific ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.